Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts

Imatinib, an inhibitor of PDGF-Rβ and other tyrosine kinase receptors, has been shown to decrease microvessel density and interstitial fluid pressure in solid tumours, thereby improving subsequent delivery of small molecules. The purpose of this study was to test whether pretreatment with imatinib i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlahovic, G, Ponce, A M, Rabbani, Z, Salahuddin, F K, Zgonjanin, L, Spasojevic, I, Vujaskovic, Z, Dewhirst, M W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360385/
https://www.ncbi.nlm.nih.gov/pubmed/17712313
http://dx.doi.org/10.1038/sj.bjc.6603941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360385/
https://www.ncbi.nlm.nih.gov/pubmed/17712313
http://dx.doi.org/10.1038/sj.bjc.6603941

Ejemplares similares